↑ parent cluster · ·
research dossier →

INTERNATIONAL CANCER

PHOENIX, AZ · EIN 860818253 · Form 990 · FY2021 · NTEE T22 · Philanthropy & Grantmaking · Small ($100K-$1M) · www.askican.org
revenue
$949K
expenses
$619K
net assets
$2.9M
employees
1
volunteers
236
program ratio
95%
mission · from form 990

ICAN ASSISTS STAGE IV CANCER PATIENTS WITH DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES, INCLUDING PHYSICIAN REFERRALS, AS WELL AS ACCESS TO MOLECULAR PROFILING AND CLINICAL TRIALS.

profile · synthesized from sources

ICAN is a patient advocacy and research advocacy organization that assists cancer patients, particularly those with Stage IV cancer, by providing personalized navigation and advocacy services. They help patients access physician referrals, molecular profiling, and clinical trials, and work to expedite the anticancer drug pipeline through lobbying and public education. The organization operates with a small staff and a global network of volunteers.

irs program accomplishments · form 990 part iii · fy2021

what they reported doing

Program narrative the organization filed with the IRS. Ordered by program spending.

  1. #1 primary $123K
    PATIENT EDUCATION/PATIENT ACCESS SERVICES--FOCUSING ON PRECISION MEDICINE, HEALTH EQUITY ISSUES, HEALTH INFORMATION TECHNOLOGY PROJECTS, AND IMPROVING PATIENT ACCESS TO DETECT AND TREAT CANCER AT ITS EARLIEST STAGES (PARTICULARLY MOLECULAR DIAGNOSTICS AND IMAGING.)
  2. #2 $82K
    MOLECULAR PROFILING/CLINICAL TRIALS MATCHING SERVICES--ADVISING PATIENTS ON THE IMPORTANCE OF MOLECULAR PROFILING (GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, AND IMMUNE CELL STUDIES;) REVIEWING PROFILING REPORTS WITH PATIENTS, CARE PARTNERS, AND MEMBERS OF ICAN'S PROFESSIONAL COUNCILS; AND CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN- TUMOR/PAN-HEME/PAN-RARE CANCER BASIS.
named programs · 9 · from sources

what they call their work

Analysis of Bottlenecks in the Drug Pipeline
Works with medical, scientific, and political communities to identify and eliminate bottlenecks in the anticancer drug pipeline at preclinical, advanced preclinical, or clinical trials stages.
Cancer Patient Advocacy Programs
Provides aggressive and effective patient advocacy, outlining promising treatment options for patients to discuss with their medical team.
Clinical Trials Advocacy Programs
Informs patients about relevant clinical trials, promising drugs via Expanded Access Programs, and Physician Requests for Single Patient Investigational New Drug (IND) Application for Compassionate or Emergency Use.
Drug Discovery and Development Projects
Historically funded organic chemistry and synthetic organic chemistry laboratories and the Babette Rosen Lobby at the Arizona State University Cancer Research Institute.
Exon 20 Group
An international research consortium battling rare cancer mutations, specifically EGFR exon 20 insertion-mutated lung cancer and HER2 insertion.
Lobbying and Legislation
Engages in lobbying at federal and state levels, spearheading legislative initiatives for cancer research funding and participating in national coalitions.
Personalized Medicine Cancer Case Navigation Programs
Provides personalized navigation services for cancer patients, empowering them to understand and discuss diagnostic and treatment options.
Pharmaceutical Licensing Expertise
Donates pro bono licensing advice to Arizona State University and the ASU Cancer Research Institute.
Public Education about New Anticancer Drugs in the Pipeline
Provides current information to the public about new cancer drugs, how to access experimental drugs, and their appropriateness for patients.
activities · 3 clusters

what they do

  • Cancer Research Infrastructure & Advocacy 6 activities
    • Advocacy for Cancer Research Funding
      Spearheaded a bill that resulted in a $10 million appropriation for cancer research by the Arizona State Legislature in 1998.
    • Advocate for state funding of cancer research
      Spearheaded legislative efforts that led to a $10 million appropriation for cancer research by the Arizona State Legislature in 1998.
    • Fund cancer research infrastructure and facilities
      Funded four organic and synthetic organic chemistry laboratories and the Babette Rosen Lobby at the Arizona State University Cancer Research Institute between 1997 and 1999, supporting physical research capacity.
    • Funding Cancer Research Facilities
      Funded four organic chemistry and synthetic organic chemistry laboratories and the Babette Rosen Lobby at the Arizona State University Cancer Research Institute from 1997 to 1999.
    • Pro Bono Licensing Advice for Research
      Donates pro bono licensing advice to Arizona State University and the ASU Cancer Research Institute.
    • Provide pro bono legal support for academic cancer research
      Has donated pro bono licensing advice to Arizona State University and the ASU Cancer Research Institute since 1999, enhancing institutional capacity in research commercialization and intellectual property.
  • Genomic Research & Molecular Profiling 2 activities
    • Cancer Research Consortium Leadership
      Co-founded and leads a research consortium focused on EGFR and HER2 exon 20 insertion mutations in rare cancers.
    • Lead research consortium on rare cancer mutations
      Co-founded and leads a research consortium focused on EGFR and HER2 exon 20 insertion mutations in rare cancers, advancing targeted scientific understanding in this specialized area.
  • Cancer Support Groups & Peer Networks 2 activities
    • Provide patient assistance for cancer diagnoses
      Has assisted patients diagnosed with various cancers since 1997, offering ongoing direct support services.
    • Support for Cancer Patients
      Assists patients diagnosed with various cancers.
financials · form 990 · fy2021

the money

revenue
Total revenue$949K
Contributions & grants$972K102%
Program service revenue$00%
Investment income$-1K-0%
Other revenue$-21K
expenses
Total expenses$619K
Program expenses95%
Admin / overhead3%
Fundraising2%
Salaries & benefits$210K
Grants paid out$145K
Largest expense lineCompensation
balance sheet
Total assets$2.90M
Cash$2.23M
Investments$20K
Liabilities$3K
Net assets$2.89M
Liquid reserves43.6 mo
2 years on record · 2020–2021 · YoY revenue -3.5%
leadership · form 990 part vii · fy2021

who runs it

paid leadership · 1
NameTitleHours/wkCompensation
MARCIA K HORN JD PRESIDENT AN 90 $201K
board members · 6
  • CATHY DALZELL — CHAIR ADIVIS
  • CHERYL J HINTZEN-GAINES — CHAIR-HONORA
  • JAMES C GREGORY — SEC/CH GOVER
  • ROBERT H TAMIS MD — VICE CHAIR S
  • SHERRY WEINSTEIN — CHAIR-TTEES-
  • SIDNEY M ROSEN ESQ — FOUNDING CHA
relationships · 9

who they work with

  • ASU Cancer Research Institute Partner — Received donated licensing advice and funding for laboratories and a lobby.
  • Alliance for a Stronger FDA Coalition — Active member of the alliance.
  • Arizona State University Partner — Received donated licensing advice and funding for laboratories and a lobby at its Cancer Research Institute.
  • Barbara Leff Government — Representative and later Arizona State Senator who sponsored a bill spearheaded by ICAN.
  • C. Owen Paepke Partner — Pro bono patent counsel providing licensing advice.
  • Coalition for the Advancement of Medical Research Coalition — Active member of the coalition.
  • Coalition of Cancer Cooperative Groups Coalition — Active member of the coalition.
  • National Coalition for Cancer Research Coalition — Active member of the coalition.
  • USA Today Mediaplanet Partner — Published ICAN's research and advocacy content in the Lung Health digital supplement.